Advarra Acquires IntegReview IRB
Advarra is pleased to announce the acquisition of IntegReview IRB. The addition of IntegReview enables Advarra to continue its expansion of comprehensive review solutions capabilities in North America.
“IntegReview and Advarra share a mission-driven passion for protecting clinical trial participants,” said Gadi Saarony, CEO of Advarra. “Our aim is to benefit clinical trials and drug development through expanded subject matter expertise, technology-enabled efficiencies, and continuing commitment to ethics, quality, and service. We are excited to welcome more talent to enhance our combined capabilities and geographic footprint.”
The Austin, Tex. headquarters for IntegReview will become the first Advarra office in the southern US. The acquisition also increases depth of expertise in many key areas, most notably in early phase research.
“We are excited to be a part of the Advarra family” said Lynn Meyer, founder and Managing Partner of IntegReview. “We were attracted to Advarra’s extensive regulatory depth and their model of integrated IRB operations and focus on building client relationships and deep collaboration with the site community.”
For more information, click here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
